AU2023311603A1 - Heterocyclic compound acting on G12D mutant KRAS protein - Google Patents

Heterocyclic compound acting on G12D mutant KRAS protein Download PDF

Info

Publication number
AU2023311603A1
AU2023311603A1 AU2023311603A AU2023311603A AU2023311603A1 AU 2023311603 A1 AU2023311603 A1 AU 2023311603A1 AU 2023311603 A AU2023311603 A AU 2023311603A AU 2023311603 A AU2023311603 A AU 2023311603A AU 2023311603 A1 AU2023311603 A1 AU 2023311603A1
Authority
AU
Australia
Prior art keywords
compound
optionally substituted
formula
chem
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2023311603A
Other languages
English (en)
Inventor
Hisao Hamaguchi
Tomoyoshi IMAIZUMI
Hiroshi Inami
Kohei Inamura
Hiroki Ishioka
Takashi Kamikubo
Kenichi Kawaguchi
Eiji Kawaminami
Kazuyuki Kuramoto
Takahiro Morikawa
Takeyuki Nagashima
Fumie Takahashi
Hideyuki Watanabe
Tomohiro Yoshinari
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Astellas Pharma Inc
Original Assignee
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc filed Critical Astellas Pharma Inc
Publication of AU2023311603A1 publication Critical patent/AU2023311603A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
AU2023311603A 2022-07-21 2023-07-20 Heterocyclic compound acting on G12D mutant KRAS protein Pending AU2023311603A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2022-116367 2022-07-21
JP2022116367 2022-07-21
PCT/JP2023/026522 WO2024019103A1 (ja) 2022-07-21 2023-07-20 G12d変異krasタンパクに作用する複素環化合物

Publications (1)

Publication Number Publication Date
AU2023311603A1 true AU2023311603A1 (en) 2025-01-09

Family

ID=89617857

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2023311603A Pending AU2023311603A1 (en) 2022-07-21 2023-07-20 Heterocyclic compound acting on G12D mutant KRAS protein

Country Status (14)

Country Link
US (1) US20250145631A1 (cg-RX-API-DMAC7.html)
EP (1) EP4559906A1 (cg-RX-API-DMAC7.html)
JP (2) JP7440710B1 (cg-RX-API-DMAC7.html)
KR (1) KR20250036820A (cg-RX-API-DMAC7.html)
CN (2) CN119894881A (cg-RX-API-DMAC7.html)
AR (1) AR129976A1 (cg-RX-API-DMAC7.html)
AU (1) AU2023311603A1 (cg-RX-API-DMAC7.html)
CA (1) CA3262030A1 (cg-RX-API-DMAC7.html)
CL (1) CL2025000158A1 (cg-RX-API-DMAC7.html)
CO (1) CO2025000804A2 (cg-RX-API-DMAC7.html)
IL (1) IL317908A (cg-RX-API-DMAC7.html)
MX (1) MX2025000772A (cg-RX-API-DMAC7.html)
TW (1) TW202409002A (cg-RX-API-DMAC7.html)
WO (1) WO2024019103A1 (cg-RX-API-DMAC7.html)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112020020307A2 (pt) 2018-04-04 2021-01-12 Arvinas Operations, Inc. Moduladores de proteólise e métodos de uso associados
PE20260006A1 (es) * 2023-01-26 2026-01-06 Arvinas Operations Inc Protacs degradadores de kras basados en cereblon y usos relacionados con los mismos
CN121487738A (zh) 2023-03-30 2026-02-06 锐新医药公司 诱导ras gtp水解的组合物和其用途
KR20260019479A (ko) 2023-05-04 2026-02-10 레볼루션 메디슨즈, 인크. Ras 관련 질환 또는 장애를 위한 병용 요법
CN122206684A (zh) 2023-06-30 2026-06-12 默克专利有限公司 用于kras蛋白降解的异双功能化合物
JP2026524477A (ja) 2023-06-30 2026-07-22 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング Krasの分解のためのヘテロ二官能性化合物
CN121889155A (zh) 2023-08-07 2026-04-17 锐新医药公司 用于治疗ras蛋白相关疾病或病症的rmc-6291
WO2025052649A1 (ja) * 2023-09-08 2025-03-13 アステラス製薬株式会社 単一の軸不斉化合物の選択的製造法
US20250109147A1 (en) 2023-09-08 2025-04-03 Gilead Sciences, Inc. Kras g12d modulating compounds
EP4778540A1 (en) 2023-09-13 2026-07-22 Astellas Pharma Inc. Antibody-drug conjugate containing heterocyclic compound having activity of inducing decomposition of g12d mutant kras protein
AU2024360465A1 (en) 2023-10-12 2026-04-09 Revolution Medicines, Inc. Macrocyclic ras inhibitors
WO2025085815A1 (en) * 2023-10-20 2025-04-24 Seed Therapeutics Us, Inc. Protac compounds binding keap1 ubiquitin ligase for targeted protein degradation
WO2025159142A1 (ja) * 2024-01-24 2025-07-31 アステラス製薬株式会社 Krasタンパクの分解を誘導するための複素環化合物
TW202545934A (zh) * 2024-02-05 2025-12-01 日商安斯泰來製藥股份有限公司 包含具有突變kras蛋白分解誘導作用之雜環化合物的抗體藥物複合體
WO2025168124A1 (zh) * 2024-02-08 2025-08-14 杭州多域生物技术有限公司 喹唑啉类化合物、其药物组合物及其应用
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
US20250375445A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026035999A1 (en) 2024-08-09 2026-02-12 Triana Biomedicines, Inc. Anaplastic lymphoma kinase (alk) degraders and uses thereof
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer
WO2026090116A2 (en) 2024-10-21 2026-04-30 Revolution Medicines, Inc. Ras inhibitors
US20260108528A1 (en) 2024-10-22 2026-04-23 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2026090245A1 (en) 2024-10-22 2026-04-30 Revolution Medicines, Inc. Use of ras inhibitors for treating cancer
WO2026106912A1 (en) 2024-11-12 2026-05-21 Revolution Medicines, Inc. Ras inhibitors
WO2026112260A1 (en) 2024-11-21 2026-05-28 Revolution Medicines, Inc. Ras inhibitors
US20260146050A1 (en) 2024-11-27 2026-05-28 Boehringer Ingelheim International Gmbh Kras degrading compounds comprising spirocyclic annulated 2 amino-3-cyano thiophenes
WO2026114957A1 (en) 2024-11-27 2026-06-04 Boehringer Ingelheim International Gmbh Spirocyclic annulated 2-amino-3-cyano thiophene derivatives as kras degraders for the treatment of cancer
WO2026122764A2 (en) 2024-12-06 2026-06-11 Revolution Medicines, Inc. Ras inhibitors
WO2026128688A2 (en) 2024-12-13 2026-06-18 Revolution Medicines, Inc. Ras inhibitors
WO2026139448A1 (en) 2024-12-23 2026-07-02 Merck Patent Gmbh Heterobifunctional compounds for the degradation of kras protein
WO2026161839A1 (en) 2025-01-27 2026-07-30 Revolution Medicines, Inc. Ras inhibitors

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102438072B1 (ko) 2012-01-12 2022-08-31 예일 유니버시티 E3 유비퀴틴 리가아제에 의한 표적 단백질 및 다른 폴리펩티드의 증진된 분해를 위한 화합물 및 방법
EP4649963A3 (en) 2014-04-14 2026-05-13 Arvinas Operations, Inc. Imide-based modulators of proteolysis and associated methods of use
WO2016049565A1 (en) 2014-09-25 2016-03-31 Araxes Pharma Llc Compositions and methods for inhibition of ras
US10011600B2 (en) 2014-09-25 2018-07-03 Araxes Pharma Llc Methods and compositions for inhibition of Ras
WO2017172979A1 (en) 2016-03-30 2017-10-05 Araxes Pharma Llc Substituted quinazoline compounds and methods of use
US10646488B2 (en) 2016-07-13 2020-05-12 Araxes Pharma Llc Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof
BR112020020307A2 (pt) * 2018-04-04 2021-01-12 Arvinas Operations, Inc. Moduladores de proteólise e métodos de uso associados
WO2020018788A1 (en) 2018-07-20 2020-01-23 Dana-Farber Cancer Institute, Inc. Degraders that target proteins via keap1
EP3897631A4 (en) * 2018-12-20 2022-11-23 C4 Therapeutics, Inc. TARGETED PROTEIN BREAKDOWN
CN114615981B (zh) 2019-08-29 2024-04-12 米拉蒂治疗股份有限公司 Kras g12d抑制剂
TW202124374A (zh) * 2019-09-13 2021-07-01 美商拜歐斯瑞克斯公司 Ras蛋白降解劑、其醫藥組合物及其治療應用
WO2021106231A1 (en) 2019-11-29 2021-06-03 Taiho Pharmaceutical Co., Ltd. A compound having inhibitory activity against kras g12d mutation
US20220370416A1 (en) 2020-04-06 2022-11-24 Arvinas Operations, Inc. Compounds and methods for targeted degradation of kras
WO2022002102A1 (en) 2020-06-30 2022-01-06 InventisBio Co., Ltd. Quinazoline compounds, preparation methods and uses thereof
EP4182313A4 (en) 2020-07-16 2024-10-09 Mirati Therapeutics, Inc. KRAS-G12D INHIBITORS
US12655160B2 (en) 2020-08-04 2026-06-16 Mirati Therapeutics, Inc. KRAS G12D inhibitors
US20240034733A1 (en) 2020-11-03 2024-02-01 Mirati Therapeutics, Inc. Kras g12d inhibitors
WO2022105855A1 (en) 2020-11-20 2022-05-27 Jacobio Pharmaceuticals Co., Ltd. Kras g12d inhibitors
US20240092803A1 (en) 2021-01-08 2024-03-21 Beigene Switzerland Gmbh Bridged compounds as kras g12d inhibitor and degrader and the use thereof
WO2022148422A1 (en) 2021-01-08 2022-07-14 Beigene, Ltd. Bridged compounds as kras g12d inhibitor and degrader and the use thereof
LT4293024T (lt) 2021-02-15 2026-05-25 Astellas Pharma Inc. Chinazolino junginys, skirtas g12d mutantinio kras baltymo degradacijai sukelti
CN115260158A (zh) 2021-04-30 2022-11-01 上海医药集团股份有限公司 一种靶向蛋白调节剂的化合物及其应用
WO2023280026A1 (zh) 2021-07-05 2023-01-12 四川科伦博泰生物医药股份有限公司 杂芳环化合物、其制备方法及用途

Also Published As

Publication number Publication date
CL2025000158A1 (es) 2025-04-04
US20250145631A1 (en) 2025-05-08
JP7440710B1 (ja) 2024-02-28
CA3262030A1 (en) 2025-06-12
JPWO2024019103A1 (cg-RX-API-DMAC7.html) 2024-01-25
CN119894881A (zh) 2025-04-25
IL317908A (en) 2025-02-01
WO2024019103A1 (ja) 2024-01-25
MX2025000772A (es) 2025-03-07
EP4559906A1 (en) 2025-05-28
AR129976A1 (es) 2024-10-16
TW202409002A (zh) 2024-03-01
JP2024056893A (ja) 2024-04-23
CN121449622A (zh) 2026-02-03
KR20250036820A (ko) 2025-03-14
CO2025000804A2 (es) 2025-02-04

Similar Documents

Publication Publication Date Title
EP4559906A1 (en) Heterocyclic compound that acts on g12d mutant kras protein
IL324684A (en) Pharmaceutical composition comprising a quinazoline compound
AU2023231912A1 (en) Heterocyclic compound for inducing degradation of g12d mutant kras protein
AU2022221145A1 (en) Quinazoline compound for inducing degradation of G12D mutant KRAS protein
CN111094289B (zh) 吡啶并嘧啶类衍生物、其制备方法及其在医药上的应用
CN116143805A (zh) 一类含氮杂环联芳基类化合物、制备方法和用途
CN111153901A (zh) 一类含氮稠杂环类shp2抑制剂化合物、制备方法和用途
JP2021513555A (ja) ピリミジン縮合環式化合物及びその製造方法、並びに使用 本出願は、出願日が2018年02月13日である中国特許出願cn201810144135.3の優先権、及び出願日が2018年06月29日である中国特許出願cn201810692211.4の優先権を主張する。本出願は上記中国出願の内容のすべてを引用する。
AU2022202886B2 (en) Quinazoline Compounds, Preparation Method, Use, and Pharmaceutical Composition Thereof
CA3211110A1 (en) 4-aminoquinazoline compound
WO2022247816A1 (zh) 含氮杂环类化合物、其制备方法及其在医药上的应用
WO2017071516A1 (zh) 一种蛋白激酶抑制剂及其制备方法和医药用途
AU2021256157A1 (en) Tricyclic compounds as EGFR inhibitors
CN113286786A (zh) Nlrp3调节剂
AU2025203211A1 (en) ErbB RECEPTOR INHIBITORS AS ANTI-TUMOR AGENTS
CN111377873B (zh) 氨基嘧啶化合物及其制备方法和用途
EP4378943A1 (en) 8-oxo-3-azabicyclo[3.2.1]octane compound or salt thereof, and preparation method therefor and use thereof
WO2022028389A1 (zh) 稠三环类衍生物、其制备方法及其在医药上的应用
TWI894448B (zh) Ctla-4小分子降解劑及其應用
CN109694351B (zh) 苯并氮杂*衍生物、其制备方法及其在医药上的应用
CA3292169A1 (en) Pharmaceutical composition comprising a quinazoline compound
EA052758B1 (ru) Гетероциклическое соединение, действующее на белок kras с мутацией g12d

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE INVENTION TITLE TO READ HETEROCYCLIC COMPOUND ACTING ON G12D MUTANT KRAS PROTEIN